Although anti-EGFR/PD-L1 BsAbs were equally potent in suppressing tumor growth as corresponding mAbs, no significant tumor difference in growth inhibition was observed between anti-EGFR/PD-L1 BsAbs and corresponding mAbs. This evidence concerns the gene EGFR and neoplasm.